***Background.*** *Clostridium difficile* infection (CDI) is associated with a 22% recurrence rate. However, few studies have focused on multiple recurrences. In order to evaluate the potential of new treatment options targeting specifically recurrences, we assessed the burden of recurrent *Clostridium difficile* infections (rCDI).

***Methods.*** A retrospective cohort of all adults diagnosed with CDI between 1998 and 2009, identified by a positive cytotoxin assay and ICD-9 CM/10 codes, living in the Sherbrooke area (Quebec, Canada). An rCDI was defined by the reappearance of diarrhea leading to a treatment, with or without a positive toxin assay or an endoscopic evidence of pseudomembranous colitis, within 14 to 60 days following the previous episode.

***Results.*** A total of 1311 patients were included (median age = 72.4 years; IQR = 54-82). Initial CDI was nosocomial in 35% of cases, followed a previous admission in 22%, and was community-acquired in 44%. The probability of having a first rCDI was 24% (291/1214) excluding deaths and total colectomies within 60 days, a second rCDI 41.3% (105/254), a third 33.3% (31/93), and a fourth or more 24.1% (7/29).

###### 

Burden of rCDI (n(%))

  Criteria                                                                                  R1 (n=291)                        R2 (n=105)      R3 (n=31)    
  ----------------------------------------------------------------------------------------- ------------------------------ ---------------- -------------- -------------
  **Treatment**                                                                             Metronidazole (PO and/or IV)    105/259 (40.5)   16/88 (18.2)   5/23 (21.7)
  Median duration (d) (IQR)                                                                 10 (4.5-14)                        7 (2-14)        6 (5-14)    
  Vancomycin PO                                                                             189/259 (73)                      81/88 (92)      20/23 (87)   
  Median duration (d) (IQR)                                                                 14 (13.5-21)                      35 (14-42)      32 (14-42)   
  **Occurrence during hospitalisation**                                                     63 (21.7)                        15/95 (15.8)      2 (6.7)     
  **Outpatient visits\***                                                                   77/226 (34.1)                    23/87 (26.4)    16/28 (57.1)  
  **Admission for rCDI**                                                                    82 (28.2)                         32 (31.7)         9 (30)     
  Length of stay (d) (median (IQR))                                                         7 (5-18)                           7 (3-14)        7 (3-10)    
  **Intensive care unit admission (ICU)**                                                   15 (5.2)                           4 (3.8)         1 (3.2)     
  **Severe episode** (WBC ≥15x10^3^/μL and/or ≥50% increase of baseline creatinine level)   86 (29.5)                         25 (23.8)        7 (22.6)    
  **Complications** (vasopressor use, ileus, toxic megacolon, perforation or colectomy)     15 (5.2)                           5 (4.8)         2 (6.5)     
  **30-day all-cause mortality**                                                            26 (8.9)                           8 (7.6)         2 (6.5)     

\*excluding patients already hospitalized

***Conclusion.*** This study addresses multiple recurrences of both community and hospital-acquired CDI, and demonstrates its substantial burden on health care resources. After each CDI, almost one third of patients needed admission, one fourth developed severe CDI and over 5% developed a complication.
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